Pentarin® Platform

A New Paradigm for Miniature Drug Conjugates
With the Pentarin® platform, Tarveda creates novel, miniature drug conjugates that incorporate innovative targeting ligands joined through linkers optimized for each conjugate to potent cancer cell killing payloads. Pentarins are designed to have optimal therapeutic properties while remaining miniature in size, enabling effective penetration rapidly into solid tumors to cause cancer cell death.

Tarveda’s approach with the Pentarin platform acknowledges the significant advances with the drug class of targeted drug conjugates – including antibody drug conjugates – and evolves the therapeutic capabilities in order to address some of the key challenges and limitations that are seen with antibody drug conjugates. In particular, Pentarins are designed to overcome the biological barriers to effective penetration into and efficacy in solid tumors.

Tarveda’s capability to advance our Pentarin platform and develop a pipeline of innovative cancer therapeutics has led to the rapid development of our first two drug candidates, PEN-221 in a Phase 1/2a clinical trial, designed for the treatment of patients with neuroendocrine cancers, including small cell lung cancer and PEN-866, which is highly selective for Heat Shock Protein 90 (HSP90) and is in a Phase 1/2a clinical trial in patients with advanced solid tumors across a range of tumor types including those previously shown to be sensitive to topoisomerase I inhibitors.

Pentarins: Designed to Maintain Miniature Size and Address Treatment Challenges in Solid Tumors 

The Pentarin platform enables the Tarveda team to design the properties of each Pentarin for optimized efficacy in the targeting of solid tumors. Our Pentarins are engineered to effectively penetrate into solid tumors to optimize efficacy, through the inherent design of the miniature drug conjugate itself, enhancing the core attributes of our drugs.

Tarveda’s team has the deep expertise to apply the company’s patented platform techniques to create Pentarins with the ideal therapeutic attributes for specific targets and solid tumor treatment. Pentarins are comprised of innovative targeting ligands linked to potent payloads and are tuned for the pharmacokinetics and biodistribution, tumor accumulation, tumor penetration, and cancer cell uptake that leads to cancer cell death into the core of tumors.

Our Team’s Extensive Understanding of Conjugate Chemistry Fuels our Unique Pentarin Platform

Tarveda’s conjugate chemistry knowledge is focused on the key attributes of creating effective miniature drug conjugates. Each component of the Pentarin is tuned for efficacy; the affinity and selectivity of each targeting ligand is maintained within each conjugate, the payloads are chosen to address the tumor type being targeted and the cleavage kinetics of each linker is optimized for the biology of the target with the chemistry to release the fully active form of each payload. As a whole, each Pentarin is designed to have the pharmacokinetics and biodistribution necessary to rapidly accumulate in tumors with sustained activity from the potent payloads to cause cancer cell death. We have developed a unique understanding of miniature drug conjugates and have developed a broad patent estate related to our novel product designs and Pentarin platform.

 

The Pentarin Platform Is Applicable to a Wide Range of Solid Tumor Targets

The Pentarin platform is the source of a growing clinical pipeline of innovative cancer therapeutics designed to overcome the biological barriers of solid tumors to make meaningful therapeutic advances for cancer patients. Each of our Pentarins is designed to remain miniature and effectively penetrate inside the tumor tissue, specifically targeting tumor cell proteins and delivering a highly potent payload to cause cell death.

Tarveda is expanding the pipeline for internal development. In conjunction with pharmaceutical collaborators, our platform can serve as the foundation for developing efficacious Pentarins by leveraging and incorporating proprietary, targeting moieties and/or payloads of pharmaceutical companies.